A recent paper published in Nature Medicine reported on the Phase I clinical trial of a mitochondria-targeting anti-cancer agent IACS-01059 in patients with acute myeloid leukemia (AML) and solid tumors [...].

1st Faculty of Medicine Charles University 121 08 Prague Czech Republic

Faculty of Science Charles University 128 00 Prague Czech Republic

General University Hospital Charles University 128 08 Prague Czech Republic

Institute of Biotechnology Czech Academy of Sciences 252 50 Prague Czech Republic

School of Pharmacy and Medical Science Griffith University Southport Qld 4222 Australia

Cancers (Basel). 29:115. PubMed

Zobrazit více v PubMed

Yap T.A., Daver N., Mahendra M., Zhang J., Kamiya-Matsuoka C., Meric-Bernstam F., Kantarjian H.M., Ravandi F., Collins M.E., Di Francesco M.E., et al. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: Phase I trials. Nat. Med. 2023;29:115–126. doi: 10.1038/s41591-022-02103-8. PubMed DOI PMC

Vangapandu H.V., Alston B., Morse J., Ayres M.L., Wierda W.G., Keating M.J., Marszalek J.R., Gandhi V. Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells. Oncotarget. 2018;9:24980–24991. doi: 10.18632/oncotarget.25166. PubMed DOI PMC

Tsuji A., Akao T., Masuya T., Murai M., Miyoshi H. IACS-010759, a potent inhibitor of glycolysis-deficient hypoxic tumor cells, inhibits mitochondrial respiratory complex I through a unique mechanism. J Biol Chem. 2020;295:7481–7491. doi: 10.1074/jbc.RA120.013366. PubMed DOI PMC

Bajpai R., Sharma A., Achreja A., Edgar C.L., Wei C., Siddiqa A.A., Gupta V.A., Matulis S.M., McBrayer S.K., Mittal A., et al. Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. Nat. Commun. 2020;11:1–16. doi: 10.1038/s41467-020-15051-z. PubMed DOI PMC

Chen D., Barsoumian H.B., Fischer G., Yang L., Verma V., Younes A.I., Hu Y., Masropour F., Klein K., Vellano C., et al. Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity. J. Immunother. Cancer. 2020;8:e000289. doi: 10.1136/jitc-2019-000289. PubMed DOI PMC

Baran N., Lodi A., Dhungana Y., Herbrich S., Collins M., Sweeney S., Pandey R., Skwarska A., Patel S., Tremblay M., et al. Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia. Nat. Commun. 2022;13:1–20. doi: 10.1038/s41467-022-30396-3. PubMed DOI PMC

Bassal M.A., Samaraweera S.E., Lim K., Benard B.A., Bailey S., Kaur S., Leo P., Toubia J., Thompson-Peach C., Nguyen T., et al. Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia. Nat. Commun. 2022;13:2614. doi: 10.1038/s41467-022-30223-9. PubMed DOI PMC

Molina J.R., Sun Y., Protopopova M., Gera S., Bandi M., Bristow C., McAfoos T., Morlacchi P., Ackroyd J., Agip A.-N.A., et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat. Med. 2020;24:1036–1046. doi: 10.1038/s41591-018-0052-4. PubMed DOI

Zhang X., Dang C.V. Time to hit pause on mitochondria-targeting cancer therapies. Nat. Med. 2023;29:29–30. doi: 10.1038/s41591-022-02129-y. PubMed DOI PMC

Alistar A., Morris B.B., Desnoyer R., Klepin H.D., Hosseinzadeh K., Clark C., Cameron A., Leyendecker J., D’Agostino R., Jr., Topaloglu U., et al. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in pa-tients with metastatic pancreatic cancer: A single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncol. 2017;18:770–778. doi: 10.1016/S1470-2045(17)30314-5. PubMed DOI PMC

Murphy M.P., Smith R.A. Targeting Antioxidants to Mitochondria by Conjugation to Lipophilic Cations. Annu. Rev. Pharmacol. Toxicol. 2007;47:629–656. doi: 10.1146/annurev.pharmtox.47.120505.105110. PubMed DOI

Zielonka J., Joseph J., Sikora A., Hardy M., Ouari O., Vasquez-Vivar J., Cheng G., Lopez M., Kalyanaraman B. Mitochondria-targeted triphenylphosphonium-based compounds: Syntheses, mechanisms of action, and therapeutic and diagnostic applications. Chem. Rev. 2017;117:10043–10120. doi: 10.1021/acs.chemrev.7b00042. PubMed DOI PMC

Rohlenova K., Sachaphibulkij K., Stursa J., Bezawork-Geleta A., Blecha J., Endaya B., Werner L., Cerny J., Zobalova R., Goodwin J., et al. Selective disruption of respiratory supercomplexes as a new strategy to suppress Her2high breast cancer. Antioxid. Redox. Signal. 2017;26:84–103. doi: 10.1089/ars.2016.6677. PubMed DOI PMC

Stemberkova-Hubackova S., Zobalova R., Dubisova M., Smigova J., Dvorakova S., Korinkova K., Ezrova Z., Endaya B., Blazkova K., Vlcak E., et al. Simultaneous targeting of mitochondrial metabolism and immune checkpoints as a new strategy for renal cancer therapy. Clin. Transl. Med. 2022;12:e645. doi: 10.1002/ctm2.645. PubMed DOI PMC

Bielcikova Z., Stursa J., Krizova L., Dong L., Spacek J., Hlousek S., Vocka M., Rohlenova K., Bartosova O., Cerny V., et al. Mitochondrially targeted tamoxifen in patients with metastatic solid tumours: An open-label, phase I/Ib single-centre trial. EClinicalMedicine. 2023;57:101873. doi: 10.1016/j.eclinm.2023.101873. PubMed DOI PMC

Neuzil J., Dong L.-F., Rohlena J., Truksa J., Ralph S.J. Classification of mitocans, anti-cancer drugs acting on mitochondria. Mitochondrion. 2012;13:199–208. doi: 10.1016/j.mito.2012.07.112. PubMed DOI

Bajzikova M., Kovarova J., Coelho A.R., Boukalova S., Oh S., Rohlenova K., Svec D., Hubackova S., Endaya B., Judasova K., et al. Reactivation of dihydroorotate dehydrogenase by respiration restores tumor growth of mitochondrial DNA-depleted cancer cells. Cell Metab. 2019;29:399–416. doi: 10.1016/j.cmet.2018.10.014. PubMed DOI PMC

Vasan K., Werner M., Chandel N.S. Mitochondrial Metabolism as a Target for Cancer Therapy. Cell Metab. 2020;32:341–352. doi: 10.1016/j.cmet.2020.06.019. PubMed DOI PMC